OXANDROLONE

Post-LOE

Novartis

ANDAORALTABLET

Approved

Dec 2006

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

3/8 — Basic

OXANDROLONE by Novartis is clinical pharmacology anabolic steroids are synthetic derivatives of testosterone. First approved in 2006.

Drug data last refreshed 20h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Anabolic steroids are synthetic derivatives of testosterone. Certain clinical effects and adverse reactions demonstrate the androgenic properties of this class of drugs. Complete dissociation of anabolic and androgenic effects has not been achieved. The actions of anabolic…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (1)

NCT05516849Phase 3Withdrawn

Placebo Versus Oxandrolone Supplementation in Trauma

Started May 2022

Trauma Injury

Company

Worked on OXANDROLONE at Novartis? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.